Industry Research Reports

Home > Reports > Service & Software > ADC Drug CDMO Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

ADC Drug CDMO Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Service & Software

Published Date: 2025-04-16

Pages: 121 Pages

Report ld: 4648681

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

ADC Drug CDMO Service Market Size(US$)

CAGR 2025-2031

19%

Market Size,2031

USD 9,627

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 3,390 million

Market Forecast in 2031(Value)

US$ 9,627 million

CAGR

19%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for ADC Drug CDMO Service was estimated to be worth US$ 2897 million in 2024 and is forecast to a readjusted size of US$ 9627 million by 2031 with a CAGR of 19.0% during the forecast period 2025-2031.

ADC drugs, also known as antibody drug coupling agents, work by coupling small molecule drugs with antibodies through linkers to form drugs. These drugs combine the high targeting ability of antibodies with the strong killing power of chemical drugs, and are considered the most promising next-generation antibody technology. To reduce research and development costs, most ADC drug development worldwide chooses outsourcing, leveraging CDMO companies to enter clinical and market more quickly. CDMO services refer to pharmaceutical and biotechnology companies outsourcing the research and production of their drugs or biological products to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its ability to customize and specialize, which can meet the specific needs of different customers at different stages.

One of the primary drivers of the ADC drug CDMO market is the increasing demand for targeted therapies, particularly in oncology. Cancer remains a leading cause of death globally, and the traditional methods of chemotherapy, while effective, often come with severe side effects that limit their use. ADCs, which combine the targeting ability of monoclonal antibodies with the potency of cytotoxic drugs, offer a more precise and effective treatment option. By delivering the toxic drug directly to cancer cells, ADCs minimize damage to healthy tissues, thereby reducing adverse effects.

The demand for ADCs is expected to increase significantly due to their ability to treat a wide range of cancers, including breast cancer, leukemia, and lung cancer. As the pipeline for ADC drugs continues to expand, pharmaceutical companies are increasingly relying on CDMOs to support the development and manufacturing of these complex therapies.

This report aims to provide a comprehensive presentation of the global market for ADC Drug CDMO Service, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of ADC Drug CDMO Service by region & country, by Type, and by Application.

The ADC Drug CDMO Service market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ADC Drug CDMO Service.

MARKET SEGMENTATION

By Company

Lonza Group
Merck KGaA
WuXi XDC
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Axplora
Aji Bio-Pharma
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
TOT Biopharm
Huadong Medicine
Innovent Biologics
Shanghai Henlius Biotech

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Cleavable Linkers
Non-cleavable Linkers

Segment by Application

Small and Medium-sized Pharmaceutical Companies
Large Pharmaceutical Companies

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of ADC Drug CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of ADC Drug CDMO Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of ADC Drug CDMO Service in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 ADC Drug CDMO Service Product Introduction

1.2 Global ADC Drug CDMO Service Market Size Forecast (2020-2031)

1.3 ADC Drug CDMO Service Market Trends & Drivers

1.3.1 ADC Drug CDMO Service Industry Trends

1.3.2 ADC Drug CDMO Service Market Drivers & Opportunity

1.3.3 ADC Drug CDMO Service Market Challenges

1.3.4 ADC Drug CDMO Service Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global ADC Drug CDMO Service Players Revenue Ranking (2024)

2.2 Global ADC Drug CDMO Service Revenue by Company (2020-2025)

2.3 Key Companies ADC Drug CDMO Service Manufacturing Base Distribution and Headquarters

2.4 Key Companies ADC Drug CDMO Service Product Offered

2.5 Key Companies Time to Begin Mass Production of ADC Drug CDMO Service

2.6 ADC Drug CDMO Service Market Competitive Analysis

2.6.1 ADC Drug CDMO Service Market Concentration Rate (2020-2025)

2.6.2 Global 5 and 10 Largest Companies by ADC Drug CDMO Service Revenue in 2024

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ADC Drug CDMO Service as of 2024)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Cleavable Linkers

3.1.2 Non-cleavable Linkers

3.2 Global ADC Drug CDMO Service Sales Value by Type

3.2.1 Global ADC Drug CDMO Service Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global ADC Drug CDMO Service Sales Value, by Type (2020-2031)

3.2.3 Global ADC Drug CDMO Service Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Small and Medium-sized Pharmaceutical Companies

4.1.2 Large Pharmaceutical Companies

4.2 Global ADC Drug CDMO Service Sales Value by Application

4.2.1 Global ADC Drug CDMO Service Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global ADC Drug CDMO Service Sales Value, by Application (2020-2031)

4.2.3 Global ADC Drug CDMO Service Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

5.1 Global ADC Drug CDMO Service Sales Value by Region

5.1.1 Global ADC Drug CDMO Service Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global ADC Drug CDMO Service Sales Value by Region (2020-2025)

5.1.3 Global ADC Drug CDMO Service Sales Value by Region (2026-2031)

5.1.4 Global ADC Drug CDMO Service Sales Value by Region (%), (2020-2031)

5.2 North America

5.2.1 North America ADC Drug CDMO Service Sales Value, 2020-2031

5.2.2 North America ADC Drug CDMO Service Sales Value by Country (%), 2024 VS 2031

5.3 Europe

5.3.1 Europe ADC Drug CDMO Service Sales Value, 2020-2031

5.3.2 Europe ADC Drug CDMO Service Sales Value by Country (%), 2024 VS 2031

5.4 Asia Pacific

5.4.1 Asia Pacific ADC Drug CDMO Service Sales Value, 2020-2031

5.4.2 Asia Pacific ADC Drug CDMO Service Sales Value by Region (%), 2024 VS 2031

5.5 South America

5.5.1 South America ADC Drug CDMO Service Sales Value, 2020-2031

5.5.2 South America ADC Drug CDMO Service Sales Value by Country (%), 2024 VS 2031

5.6 Middle East & Africa

5.6.1 Middle East & Africa ADC Drug CDMO Service Sales Value, 2020-2031

5.6.2 Middle East & Africa ADC Drug CDMO Service Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions ADC Drug CDMO Service Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions ADC Drug CDMO Service Sales Value, 2020-2031

6.3 United States

6.3.1 United States ADC Drug CDMO Service Sales Value, 2020-2031

6.3.2 United States ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

6.3.3 United States ADC Drug CDMO Service Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe ADC Drug CDMO Service Sales Value, 2020-2031

6.4.2 Europe ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe ADC Drug CDMO Service Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China ADC Drug CDMO Service Sales Value, 2020-2031

6.5.2 China ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

6.5.3 China ADC Drug CDMO Service Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan ADC Drug CDMO Service Sales Value, 2020-2031

6.6.2 Japan ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan ADC Drug CDMO Service Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea ADC Drug CDMO Service Sales Value, 2020-2031

6.7.2 South Korea ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea ADC Drug CDMO Service Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia ADC Drug CDMO Service Sales Value, 2020-2031

6.8.2 Southeast Asia ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia ADC Drug CDMO Service Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India ADC Drug CDMO Service Sales Value, 2020-2031

6.9.2 India ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

6.9.3 India ADC Drug CDMO Service Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Lonza Group

7.1.1 Lonza Group Profile

7.1.2 Lonza Group Main Business

7.1.3 Lonza Group ADC Drug CDMO Service Products, Services and Solutions

7.1.4 Lonza Group ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.1.5 Lonza Group Recent Developments

7.2 Merck KGaA

7.2.1 Merck KGaA Profile

7.2.2 Merck KGaA Main Business

7.2.3 Merck KGaA ADC Drug CDMO Service Products, Services and Solutions

7.2.4 Merck KGaA ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.2.5 Merck KGaA Recent Developments

7.3 WuXi XDC

7.3.1 WuXi XDC Profile

7.3.2 WuXi XDC Main Business

7.3.3 WuXi XDC ADC Drug CDMO Service Products, Services and Solutions

7.3.4 WuXi XDC ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.3.5 WuXi XDC Recent Developments

7.4 Abbvie

7.4.1 Abbvie Profile

7.4.2 Abbvie Main Business

7.4.3 Abbvie ADC Drug CDMO Service Products, Services and Solutions

7.4.4 Abbvie ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.4.5 Abbvie Recent Developments

7.5 Piramal Pharma Solutions

7.5.1 Piramal Pharma Solutions Profile

7.5.2 Piramal Pharma Solutions Main Business

7.5.3 Piramal Pharma Solutions ADC Drug CDMO Service Products, Services and Solutions

7.5.4 Piramal Pharma Solutions ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.5.5 Piramal Pharma Solutions Recent Developments

7.6 Catalent

7.6.1 Catalent Profile

7.6.2 Catalent Main Business

7.6.3 Catalent ADC Drug CDMO Service Products, Services and Solutions

7.6.4 Catalent ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.6.5 Catalent Recent Developments

7.7 Sterling Pharma Solutions

7.7.1 Sterling Pharma Solutions Profile

7.7.2 Sterling Pharma Solutions Main Business

7.7.3 Sterling Pharma Solutions ADC Drug CDMO Service Products, Services and Solutions

7.7.4 Sterling Pharma Solutions ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.7.5 Sterling Pharma Solutions Recent Developments

7.8 Axplora

7.8.1 Axplora Profile

7.8.2 Axplora Main Business

7.8.3 Axplora ADC Drug CDMO Service Products, Services and Solutions

7.8.4 Axplora ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.8.5 Axplora Recent Developments

7.9 Aji Bio-Pharma

7.9.1 Aji Bio-Pharma Profile

7.9.2 Aji Bio-Pharma Main Business

7.9.3 Aji Bio-Pharma ADC Drug CDMO Service Products, Services and Solutions

7.9.4 Aji Bio-Pharma ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.9.5 Aji Bio-Pharma Recent Developments

7.10 BSP Pharmaceuticals

7.10.1 BSP Pharmaceuticals Profile

7.10.2 BSP Pharmaceuticals Main Business

7.10.3 BSP Pharmaceuticals ADC Drug CDMO Service Products, Services and Solutions

7.10.4 BSP Pharmaceuticals ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.10.5 BSP Pharmaceuticals Recent Developments

7.11 Cerbios-Pharma

7.11.1 Cerbios-Pharma Profile

7.11.2 Cerbios-Pharma Main Business

7.11.3 Cerbios-Pharma ADC Drug CDMO Service Products, Services and Solutions

7.11.4 Cerbios-Pharma ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.11.5 Cerbios-Pharma Recent Developments

7.12 Goodwin Biotechnology

7.12.1 Goodwin Biotechnology Profile

7.12.2 Goodwin Biotechnology Main Business

7.12.3 Goodwin Biotechnology ADC Drug CDMO Service Products, Services and Solutions

7.12.4 Goodwin Biotechnology ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.12.5 Goodwin Biotechnology Recent Developments

7.13 TOT Biopharm

7.13.1 TOT Biopharm Profile

7.13.2 TOT Biopharm Main Business

7.13.3 TOT Biopharm ADC Drug CDMO Service Products, Services and Solutions

7.13.4 TOT Biopharm ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.13.5 TOT Biopharm Recent Developments

7.14 Huadong Medicine

7.14.1 Huadong Medicine Profile

7.14.2 Huadong Medicine Main Business

7.14.3 Huadong Medicine ADC Drug CDMO Service Products, Services and Solutions

7.14.4 Huadong Medicine ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.14.5 Huadong Medicine Recent Developments

7.15 Innovent Biologics

7.15.1 Innovent Biologics Profile

7.15.2 Innovent Biologics Main Business

7.15.3 Innovent Biologics ADC Drug CDMO Service Products, Services and Solutions

7.15.4 Innovent Biologics ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.15.5 Innovent Biologics Recent Developments

7.16 Shanghai Henlius Biotech

7.16.1 Shanghai Henlius Biotech Profile

7.16.2 Shanghai Henlius Biotech Main Business

7.16.3 Shanghai Henlius Biotech ADC Drug CDMO Service Products, Services and Solutions

7.16.4 Shanghai Henlius Biotech ADC Drug CDMO Service Revenue (US$ Million) & (2020-2025)

7.16.5 Shanghai Henlius Biotech Recent Developments

8 Industry Chain Analysis

8.1 ADC Drug CDMO Service Industrial Chain

8.2 ADC Drug CDMO Service Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 ADC Drug CDMO Service Sales Model

8.5.2 Sales Channel

8.5.3 ADC Drug CDMO Service Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. ADC Drug CDMO Service Market Trends

Table 2. ADC Drug CDMO Service Market Drivers & Opportunity

Table 3. ADC Drug CDMO Service Market Challenges

Table 4. ADC Drug CDMO Service Market Restraints

Table 5. Global ADC Drug CDMO Service Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global ADC Drug CDMO Service Revenue Market Share by Company (2020-2025)

Table 7. Key Companies ADC Drug CDMO Service Manufacturing Base Distribution and Headquarters

Table 8. Key Companies ADC Drug CDMO Service Product Type

Table 9. Key Companies Time to Begin Mass Production of ADC Drug CDMO Service

Table 10. Global ADC Drug CDMO Service Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ADC Drug CDMO Service as of 2024)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global ADC Drug CDMO Service Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 14. Global ADC Drug CDMO Service Sales Value by Type (2020-2025) & (US$ Million)

Table 15. Global ADC Drug CDMO Service Sales Value by Type (2026-2031) & (US$ Million)

Table 16. Global ADC Drug CDMO Service Sales Market Share in Value by Type (2020-2025)

Table 17. Global ADC Drug CDMO Service Sales Market Share in Value by Type (2026-2031)

Table 18. Global ADC Drug CDMO Service Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 19. Global ADC Drug CDMO Service Sales Value by Application (2020-2025) & (US$ Million)

Table 20. Global ADC Drug CDMO Service Sales Value by Application (2026-2031) & (US$ Million)

Table 21. Global ADC Drug CDMO Service Sales Market Share in Value by Application (2020-2025)

Table 22. Global ADC Drug CDMO Service Sales Market Share in Value by Application (2026-2031)

Table 23. Global ADC Drug CDMO Service Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 24. Global ADC Drug CDMO Service Sales Value by Region (2020-2025) & (US$ Million)

Table 25. Global ADC Drug CDMO Service Sales Value by Region (2026-2031) & (US$ Million)

Table 26. Global ADC Drug CDMO Service Sales Value by Region (2020-2025) & (%)

Table 27. Global ADC Drug CDMO Service Sales Value by Region (2026-2031) & (%)

Table 28. Key Countries/Regions ADC Drug CDMO Service Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 29. Key Countries/Regions ADC Drug CDMO Service Sales Value, (2020-2025) & (US$ Million)

Table 30. Key Countries/Regions ADC Drug CDMO Service Sales Value, (2026-2031) & (US$ Million)

Table 31. Lonza Group Basic Information List

Table 32. Lonza Group Description and Business Overview

Table 33. Lonza Group ADC Drug CDMO Service Products, Services and Solutions

Table 34. Revenue (US$ Million) in ADC Drug CDMO Service Business of Lonza Group (2020-2025)

Table 35. Lonza Group Recent Developments

Table 36. Merck KGaA Basic Information List

Table 37. Merck KGaA Description and Business Overview

Table 38. Merck KGaA ADC Drug CDMO Service Products, Services and Solutions

Table 39. Revenue (US$ Million) in ADC Drug CDMO Service Business of Merck KGaA (2020-2025)

Table 40. Merck KGaA Recent Developments

Table 41. WuXi XDC Basic Information List

Table 42. WuXi XDC Description and Business Overview

Table 43. WuXi XDC ADC Drug CDMO Service Products, Services and Solutions

Table 44. Revenue (US$ Million) in ADC Drug CDMO Service Business of WuXi XDC (2020-2025)

Table 45. WuXi XDC Recent Developments

Table 46. Abbvie Basic Information List

Table 47. Abbvie Description and Business Overview

Table 48. Abbvie ADC Drug CDMO Service Products, Services and Solutions

Table 49. Revenue (US$ Million) in ADC Drug CDMO Service Business of Abbvie (2020-2025)

Table 50. Abbvie Recent Developments

Table 51. Piramal Pharma Solutions Basic Information List

Table 52. Piramal Pharma Solutions Description and Business Overview

Table 53. Piramal Pharma Solutions ADC Drug CDMO Service Products, Services and Solutions

Table 54. Revenue (US$ Million) in ADC Drug CDMO Service Business of Piramal Pharma Solutions (2020-2025)

Table 55. Piramal Pharma Solutions Recent Developments

Table 56. Catalent Basic Information List

Table 57. Catalent Description and Business Overview

Table 58. Catalent ADC Drug CDMO Service Products, Services and Solutions

Table 59. Revenue (US$ Million) in ADC Drug CDMO Service Business of Catalent (2020-2025)

Table 60. Catalent Recent Developments

Table 61. Sterling Pharma Solutions Basic Information List

Table 62. Sterling Pharma Solutions Description and Business Overview

Table 63. Sterling Pharma Solutions ADC Drug CDMO Service Products, Services and Solutions

Table 64. Revenue (US$ Million) in ADC Drug CDMO Service Business of Sterling Pharma Solutions (2020-2025)

Table 65. Sterling Pharma Solutions Recent Developments

Table 66. Axplora Basic Information List

Table 67. Axplora Description and Business Overview

Table 68. Axplora ADC Drug CDMO Service Products, Services and Solutions

Table 69. Revenue (US$ Million) in ADC Drug CDMO Service Business of Axplora (2020-2025)

Table 70. Axplora Recent Developments

Table 71. Aji Bio-Pharma Basic Information List

Table 72. Aji Bio-Pharma Description and Business Overview

Table 73. Aji Bio-Pharma ADC Drug CDMO Service Products, Services and Solutions

Table 74. Revenue (US$ Million) in ADC Drug CDMO Service Business of Aji Bio-Pharma (2020-2025)

Table 75. Aji Bio-Pharma Recent Developments

Table 76. BSP Pharmaceuticals Basic Information List

Table 77. BSP Pharmaceuticals Description and Business Overview

Table 78. BSP Pharmaceuticals ADC Drug CDMO Service Products, Services and Solutions

Table 79. Revenue (US$ Million) in ADC Drug CDMO Service Business of BSP Pharmaceuticals (2020-2025)

Table 80. BSP Pharmaceuticals Recent Developments

Table 81. Cerbios-Pharma Basic Information List

Table 82. Cerbios-Pharma Description and Business Overview

Table 83. Cerbios-Pharma ADC Drug CDMO Service Products, Services and Solutions

Table 84. Revenue (US$ Million) in ADC Drug CDMO Service Business of Cerbios-Pharma (2020-2025)

Table 85. Cerbios-Pharma Recent Developments

Table 86. Goodwin Biotechnology Basic Information List

Table 87. Goodwin Biotechnology Description and Business Overview

Table 88. Goodwin Biotechnology ADC Drug CDMO Service Products, Services and Solutions

Table 89. Revenue (US$ Million) in ADC Drug CDMO Service Business of Goodwin Biotechnology (2020-2025)

Table 90. Goodwin Biotechnology Recent Developments

Table 91. TOT Biopharm Basic Information List

Table 92. TOT Biopharm Description and Business Overview

Table 93. TOT Biopharm ADC Drug CDMO Service Products, Services and Solutions

Table 94. Revenue (US$ Million) in ADC Drug CDMO Service Business of TOT Biopharm (2020-2025)

Table 95. TOT Biopharm Recent Developments

Table 96. Huadong Medicine Basic Information List

Table 97. Huadong Medicine Description and Business Overview

Table 98. Huadong Medicine ADC Drug CDMO Service Products, Services and Solutions

Table 99. Revenue (US$ Million) in ADC Drug CDMO Service Business of Huadong Medicine (2020-2025)

Table 100. Huadong Medicine Recent Developments

Table 101. Innovent Biologics Basic Information List

Table 102. Innovent Biologics Description and Business Overview

Table 103. Innovent Biologics ADC Drug CDMO Service Products, Services and Solutions

Table 104. Revenue (US$ Million) in ADC Drug CDMO Service Business of Innovent Biologics (2020-2025)

Table 105. Innovent Biologics Recent Developments

Table 106. Shanghai Henlius Biotech Basic Information List

Table 107. Shanghai Henlius Biotech Description and Business Overview

Table 108. Shanghai Henlius Biotech ADC Drug CDMO Service Products, Services and Solutions

Table 109. Revenue (US$ Million) in ADC Drug CDMO Service Business of Shanghai Henlius Biotech (2020-2025)

Table 110. Shanghai Henlius Biotech Recent Developments

Table 111. Key Raw Materials Lists

Table 112. Raw Materials Key Suppliers Lists

Table 113. ADC Drug CDMO Service Downstream Customers

Table 114. ADC Drug CDMO Service Distributors List

Table 115. Research Programs/Design for This Report

Table 116. Key Data Information from Secondary Sources

Table 117. Key Data Information from Primary Sources

List of Figures

Figure 1. ADC Drug CDMO Service Product Picture

Figure 2. Global ADC Drug CDMO Service Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global ADC Drug CDMO Service Sales Value (2020-2031) & (US$ Million)

Figure 4. ADC Drug CDMO Service Report Years Considered

Figure 5. Global ADC Drug CDMO Service Players Revenue Ranking (2024) & (US$ Million)

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by ADC Drug CDMO Service Revenue in 2024

Figure 7. ADC Drug CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 8. Cleavable Linkers Picture

Figure 9. Non-cleavable Linkers Picture

Figure 10. Global ADC Drug CDMO Service Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 11. Global ADC Drug CDMO Service Sales Value Market Share by Type, 2024 & 2031

Figure 12. Product Picture of Small and Medium-sized Pharmaceutical Companies

Figure 13. Product Picture of Large Pharmaceutical Companies

Figure 14. Global ADC Drug CDMO Service Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 15. Global ADC Drug CDMO Service Sales Value Market Share by Application, 2024 & 2031

Figure 16. North America ADC Drug CDMO Service Sales Value (2020-2031) & (US$ Million)

Figure 17. North America ADC Drug CDMO Service Sales Value by Country (%), 2024 VS 2031

Figure 18. Europe ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 19. Europe ADC Drug CDMO Service Sales Value by Country (%), 2024 VS 2031

Figure 20. Asia Pacific ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 21. Asia Pacific ADC Drug CDMO Service Sales Value by Region (%), 2024 VS 2031

Figure 22. South America ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 23. South America ADC Drug CDMO Service Sales Value by Country (%), 2024 VS 2031

Figure 24. Middle East & Africa ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 25. Middle East & Africa ADC Drug CDMO Service Sales Value by Country (%), 2024 VS 2031

Figure 26. Key Countries/Regions ADC Drug CDMO Service Sales Value (%), (2020-2031)

Figure 27. United States ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 28. United States ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

Figure 29. United States ADC Drug CDMO Service Sales Value by Application (%), 2024 VS 2031

Figure 30. Europe ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 31. Europe ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

Figure 32. Europe ADC Drug CDMO Service Sales Value by Application (%), 2024 VS 2031

Figure 33. China ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 34. China ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

Figure 35. China ADC Drug CDMO Service Sales Value by Application (%), 2024 VS 2031

Figure 36. Japan ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 37. Japan ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

Figure 38. Japan ADC Drug CDMO Service Sales Value by Application (%), 2024 VS 2031

Figure 39. South Korea ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 40. South Korea ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

Figure 41. South Korea ADC Drug CDMO Service Sales Value by Application (%), 2024 VS 2031

Figure 42. Southeast Asia ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 43. Southeast Asia ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

Figure 44. Southeast Asia ADC Drug CDMO Service Sales Value by Application (%), 2024 VS 2031

Figure 45. India ADC Drug CDMO Service Sales Value, (2020-2031) & (US$ Million)

Figure 46. India ADC Drug CDMO Service Sales Value by Type (%), 2024 VS 2031

Figure 47. India ADC Drug CDMO Service Sales Value by Application (%), 2024 VS 2031

Figure 48. ADC Drug CDMO Service Industrial Chain

Figure 49. ADC Drug CDMO Service Manufacturing Cost Structure

Figure 50. Channels of Distribution (Direct Sales, and Distribution)

Figure 51. Bottom-up and Top-down Approaches for This Report

Figure 52. Data Triangulation

Figure 53. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which region is expected to have the highest market share? zhanKai

For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 19% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.

What was the global market size of ADC Drug CDMO Service in 2031? shouQi

What was the global market size of ADC Drug CDMO Service in 2025? shouQi

What is the annual compound growth rate of the global ADC Drug CDMO Service market size from 2025 to 2031? shouQi

Which companies rank high in the global ADC Drug CDMO Service market? shouQi

Related Reports

Global ADC Drug CDMO Service Market Outlook, In‑Depth Analysis & Forecast to 2032
The global ADC Drug CDMO Service market is projected to grow from US$ 3390 million in 2025 to US$ 11270 million by 2032, at a CAGR of 19.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-26
Pages: 148
USD 4900.00
(Single User License)
Global ADC Drug CDMO Service Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global ADC Drug CDMO Service market size was US$ 3390 million in 2025 and is forecast to reach a readjusted size of US$ 11270 million by 2032 with a CAGR of 19.0% during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 110
USD 4250.00
(Single User License)
ADC Drug CDMO Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for ADC Drug CDMO Service was estimated to be worth US$ 3390 million in 2025 and is projected to reach US$ 11270 million, growing at a CAGR of 19.0% from 2026 to 2032.
Published Date: 2026-01-09
Pages: 123
USD 3950.00
(Single User License)
Global ADC Drug CDMO Service Market Research Report 2026
The global ADC Drug CDMO Service market was valued at US$ 3390 million in 2025 and is anticipated to reach US$ 11270 million by 2032, at a CAGR of 19.0% from 2026 to 2032.
Published Date: 2026-01-09
Pages: 122
USD 2900.00
(Single User License)
Global ADC Drug CDMO Service Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global ADC Drug CDMO Service market size was US$ 2897 million in 2024 and is forecast to a readjusted size of US$ 9627 million by 2031 with a CAGR of 19.0% during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 110
USD 4250.00
(Single User License)
Global ADC Drug CDMO Service Market Outlook, In‑Depth Analysis & Forecast to 2031
The global ADC Drug CDMO Service market is projected to grow from US$ 2897 million in 2024 to US$ 9627 million by 2031, at a CAGR of 19.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-08-05
Pages: 157
USD 4900.00
(Single User License)
Global ADC Drug CDMO Service Market Insights, Forecast to 2031
The global ADC Drug CDMO Service market is projected to grow from US$ 3390 million in 2025 to US$ 9627 million by 2031, at a Compound Annual Growth Rate (CAGR) of 19.0% during the forecast period.
Published Date: 2025-04-16
Pages: 157
USD 4900.00
(Single User License)
Global ADC Drug CDMO Service Market Research Report 2025
The global market for ADC Drug CDMO Service was valued at US$ 2897 million in the year 2024 and is projected to reach a revised size of US$ 9627 million by 2031, growing at a CAGR of 19.0% during the forecast period.
Published Date: 2025-04-16
Pages: 95
USD 2900.00
(Single User License)
Global and United States ADC Drug CDMO Service Market Report & Forecast 2024-2030
ADC drugs, also known as antibody drug coupling agents, work by coupling small molecule drugs with antibodies through linkers to form drugs. These drugs combine the high targeting ability of antibodies with the strong killing power of chemical drugs, and are considered the most promising next-generation antibody technology. To reduce research and development costs, most ADC drug development worldwide chooses outsourcing, leveraging CDMO companies to enter clinical and market more quickly. CDMO services refer to pharmaceutical and biotechnology companies outsourcing the research and production of their drugs or biological products to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its ability to customize and specialize, which can meet the specific needs of different customers at different stages.
Published Date: 2024-09-24
Pages: 105
USD 4350.00
(Single User License)
Global ADC Drug CDMO Service Market Research Report 2024
ADC drugs, also known as antibody drug coupling agents, work by coupling small molecule drugs with antibodies through linkers to form drugs. These drugs combine the high targeting ability of antibodies with the strong killing power of chemical drugs, and are considered the most promising next-generation antibody technology. To reduce research and development costs, most ADC drug development worldwide chooses outsourcing, leveraging CDMO companies to enter clinical and market more quickly. CDMO services refer to pharmaceutical and biotechnology companies outsourcing the research and production of their drugs or biological products to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its ability to customize and specialize, which can meet the specific needs of different customers at different stages.
Published Date: 2024-09-24
Pages: 77
USD 2900.00
(Single User License)

Global ADC Drug CDMO Service Market Outlook, In‑Depth Analysis & Forecast to 2032
The global ADC Drug CDMO Service market is projected to grow from US$ 3390 million in 2025 to US$ 11270 million by 2032, at a CAGR of 19.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 148
USD 4900.00 (Single User License)
Global ADC Drug CDMO Service Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global ADC Drug CDMO Service market size was US$ 3390 million in 2025 and is forecast to reach a readjusted size of US$ 11270 million by 2032 with a CAGR of 19.0% during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 110
USD 4250.00 (Single User License)
ADC Drug CDMO Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for ADC Drug CDMO Service was estimated to be worth US$ 3390 million in 2025 and is projected to reach US$ 11270 million, growing at a CAGR of 19.0% from 2026 to 2032.
Published: 2026-01-09
Pages: 123
USD 3950.00 (Single User License)
Global ADC Drug CDMO Service Market Research Report 2026
The global ADC Drug CDMO Service market was valued at US$ 3390 million in 2025 and is anticipated to reach US$ 11270 million by 2032, at a CAGR of 19.0% from 2026 to 2032.
Published: 2026-01-09
Pages: 122
USD 2900.00 (Single User License)
Global ADC Drug CDMO Service Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global ADC Drug CDMO Service market size was US$ 2897 million in 2024 and is forecast to a readjusted size of US$ 9627 million by 2031 with a CAGR of 19.0% during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 110
USD 4250.00 (Single User License)
Global ADC Drug CDMO Service Market Outlook, In‑Depth Analysis & Forecast to 2031
The global ADC Drug CDMO Service market is projected to grow from US$ 2897 million in 2024 to US$ 9627 million by 2031, at a CAGR of 19.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-08-05
Pages: 157
USD 4900.00 (Single User License)
Global ADC Drug CDMO Service Market Insights, Forecast to 2031
The global ADC Drug CDMO Service market is projected to grow from US$ 3390 million in 2025 to US$ 9627 million by 2031, at a Compound Annual Growth Rate (CAGR) of 19.0% during the forecast period.
Published: 2025-04-16
Pages: 157
USD 4900.00 (Single User License)
Global ADC Drug CDMO Service Market Research Report 2025
The global market for ADC Drug CDMO Service was valued at US$ 2897 million in the year 2024 and is projected to reach a revised size of US$ 9627 million by 2031, growing at a CAGR of 19.0% during the forecast period.
Published: 2025-04-16
Pages: 95
USD 2900.00 (Single User License)
Global and United States ADC Drug CDMO Service Market Report & Forecast 2024-2030
ADC drugs, also known as antibody drug coupling agents, work by coupling small molecule drugs with antibodies through linkers to form drugs. These drugs combine the high targeting ability of antibodies with the strong killing power of chemical drugs, and are considered the most promising next-generation antibody technology. To reduce research and development costs, most ADC drug development worldwide chooses outsourcing, leveraging CDMO companies to enter clinical and market more quickly. CDMO services refer to pharmaceutical and biotechnology companies outsourcing the research and production of their drugs or biological products to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its ability to customize and specialize, which can meet the specific needs of different customers at different stages.
Published: 2024-09-24
Pages: 105
USD 4350.00 (Single User License)
Global ADC Drug CDMO Service Market Research Report 2024
ADC drugs, also known as antibody drug coupling agents, work by coupling small molecule drugs with antibodies through linkers to form drugs. These drugs combine the high targeting ability of antibodies with the strong killing power of chemical drugs, and are considered the most promising next-generation antibody technology. To reduce research and development costs, most ADC drug development worldwide chooses outsourcing, leveraging CDMO companies to enter clinical and market more quickly. CDMO services refer to pharmaceutical and biotechnology companies outsourcing the research and production of their drugs or biological products to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its ability to customize and specialize, which can meet the specific needs of different customers at different stages.
Published: 2024-09-24
Pages: 77
USD 2900.00 (Single User License)